In patients with WT KRAS tumors , panitumumab-FOLFIRI significantly improved PFS versus FOLFIRI [ median 6.7 versus 4.9 months ; hazard ratio ( HR ) 0.82 [ 95 % confidence interval ( CI ) 0.69 , 0.97 ] ; P = 0.023 ] .